CIK 0001819411
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Gain Therapeutics, Inc.
Sign in to watch- Ticker
- GANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 851726310
- Phone
- +1 301-500-1556
- Business address
- 4800 HAMPDEN LANE, SUITE 200, BETHESDA, MD, 20814
- 4 Open-market buy CFO and Interim CEO bought 14,400 shares at $1.01 ($14,544)
- 4 Open-market buy Executive Chairman bought 50,000 shares at $1.00 ($49,940)
- 4 Open-market buy Director bought 17,000 shares at an average $1.22 ($20,670)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 30,000 shares at $3.86 ($115,770)
- 4 Shares withheld for taxes Chief Executive Officer gave up 6,085 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Executive Officer sold 206 shares at $2.46 ($507)
- 4 Open-market sale Chief Executive Officer sold 1,820 shares at $2.50 ($4,550)
- 4 Option exercise Chief Executive Officer acquired 825 shares (option exercise)
- 4 Option exercise Director acquired 54,900 shares (option exercise)
Page 2 of 5 · 82 filings